Sarepta announces progress on Marburg treatment

Sarepta Therapeutics, Inc., a developer of RNA-based therapeutics, announced progress on Thursday in its development of a treatment for the Marburg virus, a potential biological weapon.

Sarepta's AVI-7288 compound helped between 83 and 100 percent of non-human primates to survive infection when it was administered between one and 96 hours after infection. None of the primates treated with the placebo survived, Mass High Tech reports.

"These results are unprecedented and demonstrate a compelling proof of concept with our PMOplus chemistry platform and its ability to treat the most lethal and fast-acting viruses, without compromising efficacy of survival even after up to a four-day delay in the initiation of treatment," Chris Garabedian, the president and CEO of Sarepta, said, according to Mass High Tech. "These results represent a significant advancement toward the protection of our service members and the civilian population in the event of a bioterrorist attack. Extending the window of opportunity for effective medical intervention against lethal infections may translate to more lives saved."

Marburg, which is endemic to Africa, is classified as a Category A bioterrorism agent by the Centers for Disease Control and Prevention. Marburg hemorrhagic fever is severe and potentially fatal to humans. There are currently no Marburg treatments on the market.

The Sarepta study is being conducted under a U.S. Department of Defense contract managed by the Joint Project Manager Transformational Medical Technologies Project Management Office.

Organizations in this Story

U.S. Department of Defense

Want to get notified whenever we write about U.S. Department of Defense ?
Next time we write about U.S. Department of Defense, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.